Phase 1/2 clinical testing of Anti-Coronavirus-antibodies
Latest Information Update: 30 Mar 2020
At a glance
- Drugs Anti Coronavirus antibodies Vir Biotechnology (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Vir Biotechnology
- 30 Mar 2020 New trial record
- 25 Mar 2020 According to a Vir Biotechnology media release, clinical testing planned for this summer
Most Recent Events
Trial Overview
Purpose
Phase 1/2 clinical testing of Anti-Coronavirus-antibodies
Diseases Treated
Indication | Qualifiers | Patient Segments |
---|---|---|
COVID 2019 infections | treatment | - |
Subjects
- Subject Type patients
- Sex not stated
Trial Details
Organisations
- Sponsors Vir Biotechnology
- Affiliations Vir Biotechnology
Trial Dates
Other Details
- Design prospective
- Phase of Trial Phase I/II
- Location Unknown
- Focus Adverse reactions
Interventions
Drugs | Route | Formulation |
---|---|---|
Anti Coronavirus antibodies Vir BiotechnologyPrimary Drug | Parenteral |
-
|
Anti-Coronavirus-antibodies
Trial Centres
Trial History
Event Date | Event Type | Comment |
---|---|---|
30 Mar 2020 | New trial record | New trial record Updated 30 Mar 2020 |
25 Mar 2020 | Other trial event | According to a Vir Biotechnology media release, clinical testing planned for this summer Updated 01 Apr 2020 |
References
-
Vir Biotechnology. Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19. Media-Rel 2020;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG